Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Biological Vaccine VLA1553 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| VLA1553 Lot 1 | ACTIVE_COMPARATOR | - |
| VLA1553 Lot 2 | ACTIVE_COMPARATOR | - |
| VLA1553 Lot 3 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Biological Vaccine VLA1553 | BIOLOGICAL | Single intramuscular vaccination on Day 1 with one of three Lots of VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate |
Inclusion Criteria: 1. 18 to 45 years of age on the Day of screening 2. Able to provide informed consent 3. Generally healthy as determined by the Investigator's clinical judgement based on medical history, physical examination and screening laboratory tests 4. For women of childbearing potential: ...
VLA1553 is a vaccine candidate being developed for the prevention of Chikungunya virus infection. It is a live-attenuated vaccine designed to protect healthy adults against the disease. Valneva SE is developing it as a biological vaccine, and it is currently in Phase 3 clinical development.
VLA1553 is being developed by Valneva SE, a biopharmaceutical company whose ticker symbol is VALN. Valneva is the sponsor of the clinical program evaluating this live-attenuated Chikungunya vaccine candidate in healthy adult volunteers.
VLA1553 is in Phase 3 clinical development. It is an investigational vaccine candidate and has not been approved. The Phase 3 trial evaluating the consistency of three lots of the vaccine has been completed, with 409 participants enrolled.
VLA1553 has been studied in a Phase 3 clinical trial, NCT04786444, titled a study to demonstrate consistency of three lots of a live-attenuated Chikungunya virus vaccine candidate in healthy adults. The trial enrolled 409 participants in the United States, was randomized, double-blind, and active-controlled, and is now completed.
VLA1553 is a live-attenuated biological vaccine candidate developed by Valneva SE for Chikungunya virus infection. It is an investigational product in Phase 3 development, studied in healthy adults aged 18 years and older, and is designed to prevent Chikungunya virus infection.